The follow-up, multicentre, multinational FIGHT trial subsequently randomised 155 patients with FGFR2-IIIb IHC-positive (2+ or 3+ membranous staining in >0% of tumour cells) gastric or GEJ adenocarcinoma to FOLFOX (5-FU, folinic acid, oxaliplatin) chemotherapy plus bemarituzumab or FOLFOX plus placebo. Here, FGFR2 is linked to neoplasm.